CN115215923A - 大环广谱抗生素 - Google Patents

大环广谱抗生素 Download PDF

Info

Publication number
CN115215923A
CN115215923A CN202210868626.9A CN202210868626A CN115215923A CN 115215923 A CN115215923 A CN 115215923A CN 202210868626 A CN202210868626 A CN 202210868626A CN 115215923 A CN115215923 A CN 115215923A
Authority
CN
China
Prior art keywords
mmol
alkyl
cycloalkyl
heterocycloalkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210868626.9A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·弗里德里希·托马斯·科勒
彼得·安德鲁·史密斯
达娜·温特
布巴卡·索乌
克劳迪奥·斯图里诺
纪尧姆·佩尔蒂埃
乔纳森·布德罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN115215923A publication Critical patent/CN115215923A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Preparing Plates And Mask In Photomechanical Process (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
CN202210868626.9A 2019-05-28 2020-05-27 大环广谱抗生素 Pending CN115215923A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962853457P 2019-05-28 2019-05-28
US62/853,457 2019-05-28
CN202080040183.3A CN114007605B (zh) 2019-05-28 2020-05-27 大环广谱抗生素
PCT/US2020/034670 WO2020243155A1 (en) 2019-05-28 2020-05-27 Macrocyclic broad spectrum antibiotics

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080040183.3A Division CN114007605B (zh) 2019-05-28 2020-05-27 大环广谱抗生素

Publications (1)

Publication Number Publication Date
CN115215923A true CN115215923A (zh) 2022-10-21

Family

ID=73551292

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210868626.9A Pending CN115215923A (zh) 2019-05-28 2020-05-27 大环广谱抗生素
CN202080040183.3A Active CN114007605B (zh) 2019-05-28 2020-05-27 大环广谱抗生素

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080040183.3A Active CN114007605B (zh) 2019-05-28 2020-05-27 大环广谱抗生素

Country Status (33)

Country Link
US (2) US11208387B2 (https=)
EP (2) EP4289480A3 (https=)
JP (3) JP7078807B2 (https=)
KR (4) KR102450071B1 (https=)
CN (2) CN115215923A (https=)
AR (1) AR119019A1 (https=)
AU (2) AU2020282975B2 (https=)
BR (1) BR112021024010A2 (https=)
CA (1) CA3141853A1 (https=)
CL (1) CL2021003153A1 (https=)
CO (1) CO2021017561A2 (https=)
CR (1) CR20210682A (https=)
DK (1) DK3968983T3 (https=)
ES (1) ES2961566T3 (https=)
FI (1) FI3968983T3 (https=)
HR (1) HRP20231497T8 (https=)
HU (1) HUE063847T2 (https=)
IL (2) IL288294B (https=)
LT (1) LT3968983T (https=)
MA (1) MA55981B1 (https=)
MX (1) MX2021014554A (https=)
NZ (1) NZ783605A (https=)
PE (2) PE20240066A1 (https=)
PH (1) PH12021552972A1 (https=)
PL (1) PL3968983T3 (https=)
PT (1) PT3968983T (https=)
RS (1) RS64852B1 (https=)
SA (1) SA521430976B1 (https=)
SG (1) SG11202112920SA (https=)
SI (1) SI3968983T1 (https=)
TW (1) TWI815017B (https=)
WO (1) WO2020243155A1 (https=)
ZA (1) ZA202502195B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072635B2 (en) 2015-11-20 2021-07-27 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
KR102602837B1 (ko) * 2021-03-08 2023-11-15 차의과학대학교 산학협력단 항독력활성을 가지는 화합물
CN113583003A (zh) * 2021-08-05 2021-11-02 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
CN113933416B (zh) * 2021-09-30 2023-10-10 海南海灵化学制药有限公司 一种注射用硫酸头孢匹罗中杂质的检测方法
JP2025537754A (ja) 2022-11-11 2025-11-20 ジェネンテック， インコーポレイテッド Ｎ－アルキルアミノ酸の酵素的不斉合成
CN117946013B (zh) * 2024-01-25 2024-07-02 白银康寓信生物科技有限公司 一锅法合成5,6-二卤代-3-氨基吡嗪-2-甲酸甲酯的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104284664A (zh) * 2012-03-14 2015-01-14 斯克里普斯研究所 广谱抗生素Arylomycin类似物
WO2018149419A1 (en) * 2017-02-15 2018-08-23 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
CN108884058A (zh) * 2015-11-20 2018-11-23 阿奇克斯制药公司 大环广谱抗生素

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128280A (en) 1959-10-23 1964-04-07 Searle & Co 1-(alkoxylated/halogenated phenyl)-3-pyridylmethylureas
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
EP0862638A1 (en) 1995-11-03 1998-09-09 E.I. Du Pont De Nemours And Company Positive selection vector for bacillus sp.
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
GB9902399D0 (en) 1999-02-03 1999-03-24 Smithkline Beecham Plc Compounds
US6660832B1 (en) 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
US6951840B2 (en) 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
DE10226921A1 (de) 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
AU2004252174A1 (en) 2003-06-26 2005-01-06 Migenix Inc. Compositions of lipopeptide antibiotic derivatives and methods of use thereof
DE10358824A1 (de) 2003-12-16 2005-07-21 Bayer Healthcare Ag Antibakterielle Makrozyklen mit substituiertem Biphenyl
DE102005014247A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen VI
DE102005014245A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen V
AU2011223790A1 (en) 2010-03-01 2012-08-30 Myrexis, Inc. Compounds and therapeutic uses thereof
MX2012010381A (es) 2010-03-09 2012-11-23 Merck Canada Inc Lipoglicopeptidos en puente que potencian la actividad de antibacterianos de beta-lactama.
US20130130985A1 (en) 2010-04-01 2013-05-23 Paul Alewood Oxytocin peptide analogues
US9187524B2 (en) 2010-09-15 2015-11-17 The Scripps Research Institute Broad spectrum antibiotic arylomycin analogs
TWI642684B (zh) 2011-05-27 2018-12-01 Ｒｑｘ製藥股份有限公司 廣效性抗生素
US10501493B2 (en) 2011-05-27 2019-12-10 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
CN103159830B (zh) 2011-12-15 2017-06-20 上海来益生物药物研究开发中心有限责任公司 脂肽类化合物
FR2986154B1 (fr) 2012-01-31 2017-08-04 Pierre Fabre Dermo Cosmetique Nouveau systeme photoprotecteur
CN103788176A (zh) 2012-10-31 2014-05-14 上海来益生物药物研究开发中心有限责任公司 一种arylomycin类化合物及其制备方法和应用
EA201590871A1 (ru) 2012-11-21 2015-11-30 АрКьюЭкс ФАРМАСЪЮТИКЛС, ИНК. Макроциклические антибиотики широкого спектра действия
BR112016027232A2 (pt) 2014-05-20 2018-06-26 Genentech Inc antibióticos macrocíclicos de amplo espectro
ITUB20154591A1 (it) 2015-10-12 2017-04-12 Crestoptics S R L Apparato di microscopia confocale e relativo procedimento di acquisizione ed elaborazione di immagini
US11072635B2 (en) 2015-11-20 2021-07-27 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
CN117777229A (zh) 2017-03-27 2024-03-29 豪夫迈·罗氏有限公司 用于制备阿龙霉素环类似物的方法
JP2020536072A (ja) 2017-09-29 2020-12-10 ジェネンテック， インコーポレイテッド ペプチド抗生物質複合体およびその使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104284664A (zh) * 2012-03-14 2015-01-14 斯克里普斯研究所 广谱抗生素Arylomycin类似物
US20150045286A1 (en) * 2012-03-14 2015-02-12 The Scripps Research Institute Broad spectrum antibiotic arylomycin analogs
CN108884058A (zh) * 2015-11-20 2018-11-23 阿奇克斯制药公司 大环广谱抗生素
WO2018149419A1 (en) * 2017-02-15 2018-08-23 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETER A. SMITH ET AL: "Optimized arylomycins are a new class of Gram-negative antibiotics", 《NATURE》, vol. 561, 13 September 2018 (2018-09-13), pages 189 - 194, XP036902647, DOI: 10.1038/s41586-018-0483-6 *
刘佳佳等: "一个新的arylomycin类抗生素的研究", 《中国抗生素杂志》, vol. 39, no. 2, 25 July 2014 (2014-07-25), pages 98 - 101 *

Also Published As

Publication number Publication date
BR112021024010A2 (pt) 2022-05-17
EP3968983A1 (en) 2022-03-23
KR102688389B9 (ko) 2026-04-08
PT3968983T (pt) 2023-10-04
SG11202112920SA (en) 2021-12-30
PE20240066A1 (es) 2024-01-11
MA55981B1 (fr) 2024-02-29
AU2020282975A1 (en) 2022-01-20
AU2020282975B2 (en) 2023-02-02
CN114007605A (zh) 2022-02-01
SA521430976B1 (ar) 2023-12-11
MA55981A (fr) 2022-03-23
KR20250020719A (ko) 2025-02-11
PL3968983T3 (pl) 2024-03-18
EP3968983A4 (en) 2022-06-22
KR20220137165A (ko) 2022-10-11
EP4289480A3 (en) 2024-02-21
CR20210682A (es) 2022-06-02
JP2022525693A (ja) 2022-05-18
KR102450071B1 (ko) 2022-09-30
TW202404953A (zh) 2024-02-01
TW202110812A (zh) 2021-03-16
KR102688389B1 (ko) 2024-07-24
LT3968983T (lt) 2023-10-10
CA3141853A1 (en) 2020-12-03
AU2023200369B2 (en) 2024-10-24
JP7078807B2 (ja) 2022-05-31
IL295889B2 (en) 2025-01-01
RS64852B1 (sr) 2023-12-29
NZ790559A (en) 2025-05-02
EP4289480A2 (en) 2023-12-13
NZ783605A (en) 2022-08-26
JP7842812B2 (ja) 2026-04-08
IL295889B1 (en) 2024-09-01
PE20230383A1 (es) 2023-03-06
US20200377463A1 (en) 2020-12-03
DK3968983T3 (da) 2023-10-30
KR20240101729A (ko) 2024-07-02
HRP20231497T8 (hr) 2024-08-02
ES2961566T3 (es) 2024-03-12
EP3968983B1 (en) 2023-09-13
TWI815017B (zh) 2023-09-11
ZA202502195B (en) 2025-10-29
KR20220003629A (ko) 2022-01-10
JP2024147560A (ja) 2024-10-16
WO2020243155A1 (en) 2020-12-03
PH12021552972A1 (en) 2022-07-25
MX2021014554A (es) 2022-03-17
CL2021003153A1 (es) 2022-07-29
CN114007605B (zh) 2022-07-15
HRP20231497T1 (hr) 2024-03-01
AU2023200369A1 (en) 2023-02-23
US20220135528A1 (en) 2022-05-05
IL295889A (en) 2022-10-01
SI3968983T1 (sl) 2023-11-30
US11208387B2 (en) 2021-12-28
AR119019A1 (es) 2021-11-17
KR102764861B1 (ko) 2025-02-06
IL288294A (en) 2022-01-01
IL288294B (en) 2022-09-01
JP7508507B2 (ja) 2024-07-01
FI3968983T3 (fi) 2023-11-01
HUE063847T2 (hu) 2024-02-28
CO2021017561A2 (es) 2022-01-17
JP2022137011A (ja) 2022-09-21

Similar Documents

Publication Publication Date Title
CN114007605B (zh) 大环广谱抗生素
KR102506324B1 (ko) 알파 v 인테그린 억제제로서의 시클로부탄- 및 아제티딘-함유 모노 및 스피로시클릭 화합물
KR102764861B9 (ko) 마크로시클릭 광범위 항생제
KR102450071B9 (ko) 마크로시클릭 광범위 항생제
CN108884058A (zh) 大环广谱抗生素
CN120187733A (zh) Kif18a抑制剂及其用途
HK40076912A (en) Macrocyclic broad spectrum antibiotics
HK40060729B (en) Macrocyclic broad spectrum antibiotics
HK40060729A (en) Macrocyclic broad spectrum antibiotics
RU2834484C2 (ru) Макроциклические антибиотики широкого спектра действия
TWI919116B (zh) 大環廣效型抗生素
WO2018219478A1 (en) Heteroaryl-carboxamides as histone demethylase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076912

Country of ref document: HK

CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Michael Friedrich Thomas Kohler

Inventor after: Peter. Andrew. Smith

Inventor after: Dana Winter

Inventor after: Bubaka Sow

Inventor after: Claudio Sturino

Inventor after: Guillaume Peltier

Inventor after: Jonathan Budro

Inventor after: Stephanie Roy

Inventor before: Michael Friedrich Thomas Kohler

Inventor before: Peter. Andrew. Smith

Inventor before: Dana Winter

Inventor before: Bubaka Sow

Inventor before: Claudio Sturino

Inventor before: Guillaume Peltier

Inventor before: Jonathan Budro